Aggregation System Improves Analysis of Sub-Visible Particles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aggregation System Improves Analysis of Sub-Visible Particles


Pharmaceutical Technology
Volume 38, Issue 5, pp. 2

Shimadzu Scientific Instrument’s Aggregates Sizer Aggregation Analysis System, provides real-time quantitative evaluation of 100 nm to 10 μm subvisible particle (SVP) aggregates. By screening and identifying aggregation-prone proteins in early-stage drug development, manufacturers can save time and reduce costs. The Aggregates Sizer is capable of identifying SVP particles from invisible to visible in a single measurement in microsample quantities as small as 0.4 mL. It also enables quantitative evaluation of the concentration of those aggregates. In addition, the Aggregates Sizer can execute ongoing measurements in intervals as short as one second, allowing users to evaluate rates of change at intermediate stages during the manufacturing process. A batch cell (5 mL sample capacity) enables observation of aggregation processes as samples are mechanically stimulated.

Shimadzu Scientific Instruments

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here